Lyra Therapeutics to Present at William Blair Virtual Biotechnology Conference

WATERTOWN, Mass., July 13, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of patients with chronic rhinosinusitis (CRS), today announced that Maria Palasis, Ph.D., President and Chief Executive Officer, will present at the William Blair Virtual Biotechnology Conference, “Transitioning Biotech Breakthroughs to Commercial Success,” on Tuesday, July 18, 2023 from 10:00 – 10:45 a.m. ET.

A replay of the presentation will be available on the Investor Relations section of the Company's website at investors.lyratherapeutics.com for 7 days following the presentation.

About Lyra Therapeutics

Lyra Therapeutics, Inc. is a clinical-stage biotechnology company developing therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). Lyra has two investigational product candidates, LYR-210 and LYR-220, in late-stage development for CRS, an inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities. LYR-210 and LYR-220 are bioresorbable nasal inserts designed to be administered in a brief, in-office procedure and are intended to deliver six months of continuous mometasone furoate drug therapy (7500µg MF) to the sinonasal passages. LYR-210 is designed for surgically naïve patients and is being evaluated in the ENLIGHTEN Phase 3 clinical program, while LYR-220, an enlarged insert, is being evaluated in the BEACON Phase 2 clinical trial in patients who have recurrent symptoms despite having had prior ethmoid sinus surgery. These two product candidates are designed to treat the estimated four million CRS patients in the United States who fail medical management each year.

Contact Information:
Ellen Cavaleri, Investor Relations
615.618.6228
ecavaleri@lyratx.com